Matthew Luchini
Stock Analyst at BMO Capital
(2.05)
# 2,875
Out of 5,182 analysts
35
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $1.86 | +1,512.90% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $0.96 | +19,691.67% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $40.94 | +68.54% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $46.14 | +125.40% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $3.12 | +1,662.82% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $10.62 | +851.04% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $747.36 | -15.70% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $527.69 | -76.50% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $133.29 | -51.98% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $33.80 | -58.58% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.58 | +3,697.47% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $28 → $14 | $16.36 | -14.43% | 1 | Aug 15, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $1.86
Upside: +1,512.90%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $0.96
Upside: +19,691.67%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $40.94
Upside: +68.54%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $46.14
Upside: +125.40%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $3.12
Upside: +1,662.82%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $10.62
Upside: +851.04%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $747.36
Upside: -15.70%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $527.69
Upside: -76.50%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $133.29
Upside: -51.98%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $33.80
Upside: -58.58%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.58
Upside: +3,697.47%
Aug 15, 2018
Maintains: Market Perform
Price Target: $28 → $14
Current: $16.36
Upside: -14.43%